Stock listing
NASDAQ:PPCB Propanc Biopharma, Inc. Stock
Home listing (NASDAQ) of Propanc Biopharma, Inc.
Follow Propanc Biopharma, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:PPCB
$0.321 USD +0.004 (+1.3%)
Close on Oct 20, 2026
- Day range
- $0.308 – $0.333 USDOct 20, 2026
- Volume
- 111,112 sharesOct 20, 2026
- Market cap
- $3.16M USDAt the close on Oct 20, 2026 · price × 9.83M shares outstanding
Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:PPCB · Home | $0.321 USD | +0.004 (+1.3%) | 111,112 | $0.308 | $0.333 | $0.308 | $0.317 | Close on Oct 20, 2026 |
Daily closes
Last 3 months, Jul 20, 2026 – Oct 20, 2026 · NASDAQ:PPCB · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.321 | +0.004 | +1.3% | $0.308 | $0.333 | $0.308 | 111,112 | |
| $0.317 | -0.025 | -7.3% | $0.323 | $0.327 | $0.311 | 192,086 | |
| $0.342 | +0.001 | +0.1% | $0.351 | $0.403 | $0.325 | 2,016,065 | |
| $0.342 | -0.024 | -6.6% | $0.356 | $0.370 | $0.335 | 165,118 | |
| $0.366 | -0.047 | -11.3% | $0.428 | $0.461 | $0.365 | 827,535 | |
| $0.413 | -0.028 | -6.3% | $0.428 | $0.444 | $0.410 | 332,165 | |
| $0.440 | -0.046 | -9.4% | $0.489 | $0.490 | $0.425 | 195,600 | |
| $0.486 | +0.015 | +3.1% | $0.496 | $0.496 | $0.462 | 189,300 | |
| $0.471 | -0.028 | -5.6% | $0.497 | $0.499 | $0.461 | 194,700 | |
| $0.499 | +0.007 | +1.5% | $0.499 | $0.507 | $0.460 | 878,000 | |
| $0.491 | -0.009 | -1.7% | $0.483 | $0.530 | $0.483 | 187,800 | |
| $0.500 | -0.007 | -1.5% | $0.510 | $0.527 | $0.490 | 90,700 | |
| $0.508 | +0.006 | +1.3% | $0.506 | $0.530 | $0.500 | 72,000 | |
| $0.501 | +0.007 | +1.4% | $0.490 | $0.518 | $0.490 | 82,900 | |
| $0.494 | -0.018 | -3.6% | $0.516 | $0.522 | $0.471 | 131,400 | |
| $0.512 | -0.021 | -4.0% | $0.515 | $0.552 | $0.500 | 143,900 | |
| $0.533 | -0.097 | -15.4% | $0.615 | $0.623 | $0.518 | 421,600 | |
| $0.630 | +0.028 | +4.7% | $0.591 | $0.670 | $0.591 | 384,200 | |
| $0.602 | -0.026 | -4.2% | $0.630 | $0.667 | $0.560 | 192,300 | |
| $0.628 | -0.023 | -3.5% | $0.639 | $0.653 | $0.600 | 192,900 | |
| $0.651 | +0.021 | +3.4% | $0.647 | $0.685 | $0.638 | 424,600 | |
| $0.630 | +0.020 | +3.2% | $0.610 | $0.648 | $0.595 | 142,300 | |
| $0.610 | -0.020 | -3.2% | $0.663 | $0.666 | $0.603 | 159,900 | |
| $0.630 | -0.005 | -0.8% | $0.641 | $0.732 | $0.629 | 449,800 | |
| $0.635 | -0.185 | -22.6% | $0.848 | $0.860 | $0.625 | 1,103,000 | |
| $0.820 | -0.030 | -3.5% | $0.860 | $0.880 | $0.813 | 173,800 | |
| $0.850 | -0.071 | -7.7% | $0.900 | $0.911 | $0.828 | 280,900 | |
| $0.921 | -0.022 | -2.3% | $0.922 | $0.935 | $0.874 | 227,600 | |
| $0.943 | -0.047 | -4.8% | $0.973 | $0.976 | $0.936 | 128,300 | |
| $0.990 | -0.040 | -3.9% | $1.010 | $1.030 | $0.915 | 304,400 | |
| $1.030 | +0.020 | +2.0% | $1.020 | $1.040 | $0.991 | 173,700 | |
| $1.010 | -0.010 | -1.0% | $1.050 | $1.050 | $0.972 | 194,400 | |
| $1.020 | -0.010 | -1.0% | $1.030 | $1.035 | $0.970 | 343,700 | |
| $1.030 | -0.100 | -8.8% | $1.100 | $1.160 | $1.000 | 529,900 | |
| $1.130 | -0.220 | -16.3% | $1.270 | $1.275 | $1.110 | 623,200 | |
| $1.350 | 0.000 | 0.0% | $1.290 | $1.480 | $1.250 | 797,600 | |
| $1.350 | -0.880 | -39.5% | $1.930 | $1.940 | $1.310 | 4,056,900 | |
| $2.230 | +1.160 | +108.4% | $3.510 | $4.130 | $1.980 | 97,317,100 | |
| $1.070 | -0.060 | -5.3% | $1.119 | $1.120 | $1.070 | 9,200 | |
| $1.130 | -0.025 | -2.2% | $1.140 | $1.160 | $1.080 | 15,000 | |
| $1.155 | +0.075 | +6.9% | $1.100 | $1.190 | $1.080 | 23,000 | |
| $1.080 | -0.020 | -1.8% | $1.120 | $1.120 | $1.050 | 25,100 | |
| $1.100 | -0.040 | -3.5% | $1.130 | $1.180 | $1.100 | 20,800 | |
| $1.140 | -0.020 | -1.7% | $1.185 | $1.185 | $1.100 | 36,900 | |
| $1.160 | +0.010 | +0.9% | $1.120 | $1.194 | $1.100 | 33,100 | |
| $1.150 | -0.070 | -5.7% | $1.250 | $1.270 | $1.150 | 46,500 | |
| $1.220 | 0.000 | 0.0% | $1.210 | $1.290 | $1.200 | 39,400 | |
| $1.220 | +0.010 | +0.8% | $1.240 | $1.260 | $1.200 | 34,500 | |
| $1.210 | +0.040 | +3.4% | $1.230 | $1.260 | $1.170 | 39,000 | |
| $1.170 | +0.020 | +1.7% | $1.180 | $1.240 | $1.160 | 44,100 | |
| $1.150 | -0.050 | -4.2% | $1.200 | $1.238 | $1.065 | 83,600 | |
| $1.200 | -0.160 | -11.8% | $1.220 | $1.260 | $1.180 | 193,400 | |
| $1.360 | +0.180 | +15.3% | $1.250 | $1.600 | $1.100 | 1,234,800 | |
| $1.180 | +0.160 | +15.7% | $1.060 | $1.320 | $1.050 | 595,000 | |
| $1.020 | -0.030 | -2.9% | $1.100 | $1.100 | $0.978 | 47,600 | |
| $1.050 | +0.040 | +4.0% | $1.020 | $1.070 | $1.000 | 75,500 | |
| $1.010 | -0.030 | -2.9% | $1.070 | $1.080 | $0.950 | 39,300 | |
| $1.040 | +0.050 | +5.1% | $1.000 | $1.084 | $0.970 | 46,300 | |
| $0.990 | -0.220 | -18.2% | $1.190 | $1.240 | $0.950 | 187,400 | |
| $1.210 | -0.110 | -8.3% | $1.290 | $1.300 | $1.170 | 69,300 | |
| $1.320 | -0.050 | -3.6% | $1.330 | $1.360 | $1.200 | 50,300 | |
| $1.370 | -0.080 | -5.5% | $1.440 | $1.460 | $1.350 | 15,500 | |
| $1.450 | +0.010 | +0.7% | $1.440 | $1.530 | $1.430 | 38,600 | |
| $1.440 | +0.060 | +4.3% | $1.410 | $1.470 | $1.360 | 104,800 | |
| $1.380 | 0.000 | 0.0% | $1.430 | $1.450 | $1.345 | 47,900 | |
| $1.380 | -0.110 | -7.4% | $1.500 | $1.500 | $1.330 | 115,100 |
- Ticker
- NASDAQ:PPCB
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Oct 16, 2026
Propanc Biopharma’s Lead Asset PRP Reprograms Chemotherapy-Resistant Pancreatic Cancer Cells
Latest news
Propanc Biopharma’s Lead Asset PRP Reprograms Chemotherapy-Resistant Pancreatic Cancer Cells
Oct 16, 2026
Closed $0.342 (+0.1%) on Oct 16, 2026
Propanc Biopharma Announces Publication of Pilot Study Demonstrating Potent Anti-Tumor Efficacy of PRP Pancreatic Proenzyme Formulation in Pancreatic & Ovarian Cancer
Oct 14, 2026
Closed $0.366 (-11.3%) on Oct 14, 2026
Propanc Biopharma Reports Data Showing 90% Tumor Growth Inhibition with PRP in Pancreatic Cancer Models, Contrasting Profile with Revolution Medicines’ Daraxonrasib
Oct 7, 2026
Closed $0.499 (+1.5%) on Oct 7, 2026
Propanc Biopharma Provides Corporate Update & Year-End June 30, 2025-26, Financial Results
Sep 29, 2026
Closed $0.512 (-4.0%) on Sep 29, 2026
Propanc Biopharma Highlights Differentiated PRP Pancreatic Cancer Data Versus Emerging Pan-RAS Program ERAS-0015
Sep 22, 2026
Closed $0.651 (+3.4%) on Sep 22, 2026
Propanc Biopharma Positions PRP’s EMT-Reversal Mechanism as a Complementary Backbone to Emerging RAS Inhibitors from Revolution Medicines, Inc. and Erasca, Inc.
Sep 16, 2026
Closed $0.635 (-22.6%) on Sep 16, 2026
Propanc Biopharma to Initiate World-First Phase 1b First-in-Human Study of PRP in February 2027
Sep 9, 2026
Closed $0.99 (-3.9%) on Sep 9, 2026
Propanc Biopharma Announces Compelling New Preclinical Pancreatic Cancer Data for PRP Showing >90% Tumor Growth Inhibition and >2.5-Fold Survival Benefit
Aug 27, 2026
Closed $2.23 (+108.4%) on Aug 27, 2026
Propanc Biopharma Clears Path for World-First Phase 1b Clinical Study of Breakthrough Cancer Therapy PRP
Aug 18, 2026
Closed $1.16 (+0.9%) on Aug 18, 2026
Propanc Biopharma Highlights Differentiated Proenzyme Therapy PRP as a Potential Therapy of Choice Against RAS-Driven Cancers
Aug 12, 2026
Closed $1.21 (+3.4%) on Aug 12, 2026
Decks
Investor Presentation (April 2024)
Investor deck · 26 slides · Apr 10, 2024
Investor Presentation (February 2019)
Investor deck · 25 slides · Feb 12, 2019
Investor Presentation (September 2018)
Investor deck · 32 slides · Sep 7, 2018
Investor Presentation (June 2017)
Investor deck · 38 slides · Jun 1, 2017
Propanc Biopharma, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 38 in the last 12 months · 106 in all · newest Oct 16, 2026 · oldest 2019
- Decks
- 5 decks · latest Apr 10, 2024
Where Propanc Biopharma, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:PPCB · Home listing · This page | NASDAQ | United States | USD |
| BOATS:PPCB | BOATS | United States | USD |
Log in to ask 6ix AI your own questions about Propanc Biopharma, Inc.